Base de dados : MEDLINE
Pesquisa : D12.776.543.750.783 [Categoria DeCS]
Referências encontradas : 284 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 29 ir para página                         

  1 / 284 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27777266
[Au] Autor:De Vriese AS; Glassock RJ; Nath KA; Sethi S; Fervenza FC
[Ad] Endereço:Division of Nephrology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium; an.devriese@azsintjan.be fervenza.fernando@mayo.edu.
[Ti] Título:A Proposal for a Serology-Based Approach to Membranous Nephropathy.
[So] Source:J Am Soc Nephrol;28(2):421-430, 2017 Feb.
[Is] ISSN:1533-3450
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Primary membranous nephropathy (MN) is an autoimmune disease mainly caused by autoantibodies against the recently discovered podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-containing 7A (THSD7A). Assays for quantitative assessment of anti-PLA2R antibodies are commercially available, but a semiquantitative test to detect anti-THSD7A antibodies has been only recently developed. The presence or absence of anti-PLA2R and anti-THSD7A antibodies adds important information to clinical and immunopathologic data in discriminating between primary and secondary MN. Levels of anti-PLA2R antibodies and possibly, anti-THSD7A antibodies tightly correlate with disease activity. Low baseline and decreasing anti-PLA2R antibody levels strongly predict spontaneous remission, thus favoring conservative therapy. Conversely, high baseline or increasing anti-PLA2R antibody levels associate with nephrotic syndrome and progressive loss of kidney function, thereby encouraging prompt initiation of immunosuppressive therapy. Serum anti-PLA2R antibody profiles reliably predict response to therapy, and levels at completion of therapy may forecast long-term outcome. Re-emergence of or increase in antibody titers precedes a clinical relapse. Persistence or reappearance of anti-PLA2R antibodies after kidney transplant predicts development of recurrent disease. We propose that an individualized serology-based approach to MN, used to complement and refine the traditional proteinuria-driven approach, will improve the outcome in this disease.
[Mh] Termos MeSH primário: Glomerulonefrite Membranosa/sangue
Glomerulonefrite Membranosa/diagnóstico
[Mh] Termos MeSH secundário: Algoritmos
Autoanticorpos/sangue
Glomerulonefrite Membranosa/terapia
Seres Humanos
Transplante de Rim
Prognóstico
Receptores da Fosfolipase A2/imunologia
Testes Sorológicos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Autoantibodies); 0 (PLA2R1 protein, human); 0 (Receptors, Phospholipase A2)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[St] Status:MEDLINE
[do] DOI:10.1681/ASN.2016070776


  2 / 284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953655
[Au] Autor:Lu C; Zuo K; Lu Y; Liang S; Huang X; Zeng C; Zhang J; An Y; Wang J
[Ad] Endereço:Department of National Clinical Research Center of Kidney Disease, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
[Ti] Título:Apolipoprotein A-1-related amyloidosis 2 case reports and review of the literature.
[So] Source:Medicine (Baltimore);96(39):e8148, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Apolipoprotein A-1 (ApoA-1)-related amyloidosis is characterized by the deposition of ApoA-1 in various organs and can be either hereditary or nonhereditary. It is rare and easily misdiagnosed. Renal involvement is common in hereditary ApoA-1 amyloidosis, but rare in the nonhereditary form. PATIENT CONCERNS: We reported two cases with ApoA-1 amyloidosis, a 64-year-old man suffering from nephrotic syndrome and a 40-year-old man with nephrotic syndrome and splenomegaly. Renal biopsies revealed glomerular, interstitial and vascular amyloid deposits and positive phospholipase A2 receptor staining in the glomerular capillary loop in case 1, and mesangial amyloid deposits in case 2. DIAGNOSES: After immunostaining failed to determine the specific amyloid protein, proteomic analysis of amyloid deposits by mass spectrometry was performed and demonstrated the ApoA-1 origin of the amyloid. Genetic testing revealed no mutation of the APOA1 gene in case 1 but a heterozygous mutation, Trp74Arg, in case 2. Case 1 was thus diagnosed as nonhereditary ApoA-1 associated renal amyloidosis with membranous nephropathy, and case 2 as hereditary ApoA-1 amyloidosis with multiorgan injuries (kidney and spleen) and a positive family history. INTERVENTIONS: Case 1 was treated with glucocorticoid combined with cyclosporine. Case 2 was treated with calcitriol and angiotensin converting enzyme inhibitors. OUTCOMES: Two cases were followed up for 5 months and 2 years, respectively; and case 1 was found to have attenuated proteinuria while case 2 had an elevation of cholestasis indices along with renal insufficiency. LESSONS: Proteomic analysis by mass spectrometry of the amyloid deposits combined with genetic analysis can provide accurate diagnosis of ApoA-1 amyloidosis. Besides, these 2 cases expand our knowledge of ApoA-1-related renal amyloidosis.
[Mh] Termos MeSH primário: Amiloidose Familiar
Amiloidose
Apolipoproteína A-I/metabolismo
Rim/patologia
Síndrome Nefrótica
Placa Amiloide
Esplenomegalia
[Mh] Termos MeSH secundário: Adulto
Amiloidose/diagnóstico
Amiloidose/metabolismo
Amiloidose/fisiopatologia
Amiloidose Familiar/diagnóstico
Amiloidose Familiar/metabolismo
Amiloidose Familiar/fisiopatologia
Inibidores da Enzima Conversora de Angiotensina/administração & dosagem
Calcitriol/administração & dosagem
Agonistas dos Canais de Cálcio/administração & dosagem
Ciclosporina/administração & dosagem
Diagnóstico Diferencial
Inibidores Enzimáticos/administração & dosagem
Glucocorticoides/administração & dosagem
Seres Humanos
Imunossupressores/administração & dosagem
Masculino
Espectrometria de Massas/métodos
Conduta do Tratamento Medicamentoso
Meia-Idade
Síndrome Nefrótica/diagnóstico
Síndrome Nefrótica/etiologia
Seleção de Pacientes
Placa Amiloide/metabolismo
Placa Amiloide/patologia
Receptores da Fosfolipase A2/metabolismo
Esplenomegalia/diagnóstico
Esplenomegalia/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Apolipoprotein A-I); 0 (Calcium Channel Agonists); 0 (Enzyme Inhibitors); 0 (Glucocorticoids); 0 (Immunosuppressive Agents); 0 (Receptors, Phospholipase A2); 83HN0GTJ6D (Cyclosporine); FXC9231JVH (Calcitriol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008148


  3 / 284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28674044
[Au] Autor:Beck LH
[Ad] Endereço:Renal Section, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts Laurence.Beck@bmc.org lhbeckjr@bu.edu.
[Ti] Título:PLA2R and THSD7A: Disparate Paths to the Same Disease?
[So] Source:J Am Soc Nephrol;28(9):2579-2589, 2017 Sep.
[Is] ISSN:1533-3450
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) are the two major autoantigens in primary membranous nephropathy (MN), and define two molecular subclasses of this disease. Both proteins are large transmembrane glycoproteins expressed by the podocyte, and both induce IgG4-predominant humoral immune responses that produce circulating autoantibodies that can be used clinically for diagnostic and monitoring purposes. The biologic roles of these proteins remain speculative, although several features of THSD7A suggest a role in adhesion. PLA2R-associated MN was initially found to associate with risk alleles within , but subsequent studies have shifted the focus to the HLA-DRB locus. Three distinct humoral epitope-containing regions have been defined within the extracellular portion of PLA2R, and it appears that the number of targeted epitopes may determine disease severity. Although similar information is not yet available for THSD7A-associated MN, this form of MN may have a unique association with malignancy. Finally, it appears likely that other autoantigens in primary MN exist. Although protocols similar to those that identified PLA2R and THSD7A may be successful in the identification of novel antigenic targets in MN, newer techniques such as laser-capture mass spectrometry or protein arrays may be helpful as well.
[Mh] Termos MeSH primário: Autoantígenos/imunologia
Glomerulonefrite Membranosa/imunologia
Neoplasias/imunologia
Receptores da Fosfolipase A2/genética
Receptores da Fosfolipase A2/imunologia
Trombospondinas/imunologia
[Mh] Termos MeSH secundário: Autoanticorpos
Autoantígenos/genética
Epitopos/genética
Cadeias alfa de HLA-DQ/genética
Cadeias beta de HLA-DR/genética
Seres Humanos
Imunoglobulina G
Podócitos/metabolismo
Receptores da Fosfolipase A2/isolamento & purificação
Receptores da Fosfolipase A2/metabolismo
Trombospondinas/isolamento & purificação
Trombospondinas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Autoantigens); 0 (Epitopes); 0 (HLA-DQ alpha-Chains); 0 (HLA-DQA1 antigen); 0 (HLA-DR beta-Chains); 0 (Immunoglobulin G); 0 (Receptors, Phospholipase A2); 0 (Thrombospondins); 0 (thrombospondin type I domain containing 7A protein, human)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1681/ASN.2017020178


  4 / 284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28614271
[Au] Autor:Pang L; Zhang AM; Li HX; Du JL; Jiao LL; Duan N; Liu Y; Yu D
[Ad] Endereço:aDepartment of Clinical Laboratory, Peking University First Hospital, Beijing bDepartment of Clinical Laboratory, Tianjin Nankai Hospital, Tianjin, The People's Republic of China.
[Ti] Título:Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: A cross-sectional study.
[So] Source:Medicine (Baltimore);96(24):e7218, 2017 Jun.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:M-type phospholipase A2 receptor (PLA2R) is the major target antigen in primary membranous nephropathy (PMN). Previous studies have evaluated the diagnostic value of serum anti-PLA2R antibody. However, the correlation of serum anti-PLA2R antibody and glomerular PLA2R deposition, and their association with clinical characteristics need to be further evaluated.A total of 136 patients were involved as inception group because serum anti-PLA2R antibody and glomerular PLA2R antigen were simultaneously measured. We examined serum anti-PLA2R antibody by ELISA and glomerular PLA2R deposition by immunofluorescence assay.Positive serum anti-PLA2R antibody and glomerular PLA2R deposition were seen in 58.8% (80/136) and 95.6% (130/136) patients, respectively (P < .001). Proteinuria, serum total protein, serum albumin, serum creatinine, and estimated glomerular filtration rate (eGFR) had significant differences between patients with serum anti-PLA2R antibody and those without. Serum anti-PLA2R antibody levels were correlated with serum albumin, serum creatinine, eGFR, and proteinuria. Glomerular PLA2R deposition intensities were weakly correlated with proteinuria. Unexpectedly, there was a positive correlation rather than a negative correlation between glomerular PLA2R deposition intensity and eGFR.In conclusion, serum anti-PLA2R antibody is more closely correlated with disease activity and renal function than glomerular PLA2R deposition.
[Mh] Termos MeSH primário: Autoanticorpos/sangue
Glomerulonefrite Membranosa/metabolismo
Imunoglobulina G/metabolismo
Rim/metabolismo
Receptores da Fosfolipase A2/metabolismo
[Mh] Termos MeSH secundário: Biomarcadores/metabolismo
China
Creatinina/sangue
Estudos Transversais
Ensaio de Imunoadsorção Enzimática
Imunofluorescência
Taxa de Filtração Glomerular
Glomerulonefrite Membranosa/tratamento farmacológico
Glomerulonefrite Membranosa/patologia
Seres Humanos
Rim/patologia
Proteinúria/tratamento farmacológico
Proteinúria/metabolismo
Proteinúria/patologia
Estudos Retrospectivos
Sensibilidade e Especificidade
Albumina Sérica/análise
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Biomarkers); 0 (Immunoglobulin G); 0 (PLA2R1 protein, human); 0 (Receptors, Phospholipase A2); 0 (Serum Albumin); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170714
[Lr] Data última revisão:
170714
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007218


  5 / 284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28397717
[Au] Autor:Xu NX; Xie QH; Sun ZX; Wang J; Li Y; Wang L; Liu SJ; Xue J; Hao CM
[Ad] Endereço:Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200040, China.
[Ti] Título:Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy.
[So] Source:Chin Med J (Engl);130(8):892-898, 2017 Apr 20.
[Is] ISSN:0366-6999
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: According to the renal phospholipase A2 receptor (PLA2R) immunohistochemistry, idiopathic membranous nephropathy (iMN) could be categorized into PLA2R-associated and non-PLA2R-associated iMN. This study aimed to examine whether the non-PLA2R-associated iMN had any difference in clinical features compared with PLA2R-associated iMN. METHODS: A total of 231 adult patients diagnosed as iMN were recruited to this retrospective study. Renal PLA2R expression was examined by immunofluorescence. Among these patients, 186 (80.5%) with complete baseline clinical data were used for further study. Urinary protein excretion, serum albumin, and creatinine were analyzed. For those patients with follow-up longer than 1 year, the relationship between PLA2R and response to immunosuppressants were analyzed. The t-test was used for parametric analysis and the Mann-Whitney U-test was used for nonparametric analysis. Categorical variables were described as frequencies or percentages, and the data were analyzed with Pearson's Chi-square test or Fisher's exact test. RESULTS: Of the 231 iMN patients, 189 showed renal detectable PLA2R expression (81.8%). The baseline serum creatinine, serum albumin, and urine protein excretion were not significantly different between PLA2R-associated (n = 145) and non-PLA2R-associated iMN patients (n = 41). However, about 1/3 of the non-PLA2R-associated iMN had abnormal serological tests, significantly more common than PLA2R-associated iMN (31.7% vs. 8.3%, P = 0.000). The non-PLA2R-associated iMN had lower C4 levels compared with PLA2R-associated iMN (P = 0.004). The non-PLA2R-associated iMN patients also showed a better response to immunosuppressants (complete remission [CR] 42.9%; partial remission [PR] 14.3%) compared with PLA2R-associated iMN (CR 3.2%; PR 48.4%, P = 0.004) at the 3rd month. CONCLUSIONS: There were no significant differences in serum creatinine, albumin, and urine protein excretion between PLA2R-associated and non-PLA2R-associated iMN, while the non-PLA2R-associated iMN patients showed more abnormal serological tests. The non-PLA2R-associated iMN seemed to respond more quickly to the immunosuppressive therapy compared with PLA2R-associated iMN.
[Mh] Termos MeSH primário: Glomerulonefrite Membranosa/metabolismo
Receptores da Fosfolipase A2/metabolismo
[Mh] Termos MeSH secundário: Adulto
Autoanticorpos/metabolismo
Feminino
Glomerulonefrite Membranosa/tratamento farmacológico
Glomerulonefrite Membranosa/patologia
Glomerulonefrite Membranosa/urina
Seres Humanos
Imunossupressores/uso terapêutico
Rim/metabolismo
Rim/patologia
Masculino
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Immunosuppressive Agents); 0 (Receptors, Phospholipase A2)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.4103/0366-6999.204096


  6 / 284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28257452
[Au] Autor:Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P
[Ad] Endereço:Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Department of Nephrology and Transplantation, Créteil, France.
[Ti] Título:Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.
[So] Source:PLoS One;12(3):e0173201, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Clinical course of membranous nephropathy (MN) is difficult to predict. Measurement of circulating anti-PLA2R autoantibodies (PLA2R-Ab) and detection in immune deposits of PLA2R antigen (PLA2R-Ag) are major advances in disease understanding. We evaluated the clinical significance of these biomarkers. METHODS: In this 14-year retrospective study, we collected data from 108 MN patients and assessed the relationship between clinical course, PLA2R-Ab and PLA2R-Ag. We also assessed THSD7A status. RESULTS: Eighty-five patients suffered from primary MN (PMN) and 23 patients from a secondary form. The median follow-up was 30.4 months [interquartile range, 17.7;56.7]. Among the 77 patients with PMN and available serum and/or biopsy, 69 (89.6%) had PLA2R-related disease as shown by anti-PLA2R-Ab and/or PLA2R-Ag, while 8 patients (8/77, 10.4%) were negative for both. There was no significant difference between these two groups in age at diagnosis and outcome assessed by proteinuria, serum albumin level and eGFR. Two of the 8 negative patients were positive for THSD7A. In patients with PLA2R related PMN, younger age, lower proteinuria, higher eGFR, and lower PLA2R-Ab level at baseline and after 6 months were associated with remission of proteinuria. Initial PLA2R-Ab titer ≤ 97.6 RU/mL and complete depletion of PLA2R-Ab within 6-months were significantly associated with spontaneous remission at the end of follow-up. In rituximab treated patients, lower PLA2R-Ab titer at initiation of treatment, and absence of PLA2R-Ab and higher serum albumin level at 3 months were significantly associated with remission. Noticeably, 81.8% of the patients who achieved remission completely cleared PLA2R-Ab. Depletion of PLA2R-Ab and increase of serum albumin level preceded the decrease of proteinuria. CONCLUSION: Assessment of PLA2R autoimmunity is essential for patient management. Combination of PLA2R-Ab and PLA2R-Ag increases diagnosis sensitivity. PLA2R-Ab titer is a biomarker of disease severity at initial assessment, and the kinetics of the antibody are significantly correlated to disease evolution.
[Mh] Termos MeSH primário: Anticorpos Anti-Idiotípicos/sangue
Antígenos/sangue
Autoimunidade
Glomerulonefrite Membranosa/sangue
Receptores da Fosfolipase A2/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Anticorpos Anti-Idiotípicos/imunologia
Antígenos/imunologia
Biópsia
Feminino
Glomerulonefrite Membranosa/imunologia
Glomerulonefrite Membranosa/patologia
Seres Humanos
Masculino
Meia-Idade
Prognóstico
Proteinúria/sangue
Proteinúria/imunologia
Receptor do Fator de Crescimento Epidérmico/sangue
Receptores da Fosfolipase A2/imunologia
Albumina Sérica/metabolismo
Trombospondinas/sangue
Trombospondinas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Anti-Idiotypic); 0 (Antigens); 0 (PLA2R1 protein, human); 0 (Receptors, Phospholipase A2); 0 (Serum Albumin); 0 (Thrombospondins); 0 (thrombospondin type I domain containing 7A protein, human); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0173201


  7 / 284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28212809
[Au] Autor:Lee JH; Jo YS; Kim MS; Yoo NJ; Lee SH
[Ad] Endereço:Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea.
[Ti] Título:Inactivating frameshift mutation of putative tumor suppressor genes PLA2R1 and SRPK1 in gastric and colorectal cancers.
[So] Source:Cancer Genet;210:34-35, 2017 01.
[Is] ISSN:2210-7762
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Neoplasias Colorretais/genética
Mutação da Fase de Leitura/genética
Genes Supressores de Tumor
Proteínas Serina-Treonina Quinases/genética
Receptores da Fosfolipase A2/genética
Neoplasias Gástricas/genética
[Mh] Termos MeSH secundário: Seres Humanos
Repetições de Microssatélites/genética
Polimorfismo Conformacional de Fita Simples
[Pt] Tipo de publicação:LETTER; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (PLA2R1 protein, human); 0 (Receptors, Phospholipase A2); EC 2.7.1.- (SRPK1 protein, human); EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170219
[St] Status:MEDLINE


  8 / 284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28167276
[Au] Autor:Burbelo PD; Beck LH; Waldman M
[Ad] Endereço:Dental Clinical Research Core, NIDCR, NIH, Bethesda, MD, United States. Electronic address: burbelop@nidcr.nih.gov.
[Ti] Título:Detection and monitoring PLA R autoantibodies by LIPS in membranous nephropathy.
[So] Source:J Immunol Methods;444:17-23, 2017 May.
[Is] ISSN:1872-7905
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Autoantibodies against the M-type phospholipase A receptor (PLA R) are specific markers for primary membranous nephropathy (MN). Quantification of PLA R autoantibodies is an important, noninvasive tool that facilitates the diagnosis and monitoring of primary MN. In this report we describe a highly quantitative luciferase immunoprecipitation systems (LIPS) assay for detecting PLA R autoantibodies. For these studies, a cDNA fragment encoding the first 858 amino acids of PLA R protein was cloned to generate N-terminal antigen fusion constructs with Gaussia luciferase (Gluc) and Nano luciferase (NanoLuc) reporters. Following transfection, crude cell extracts containing the recombinant PLA R-luciferase fusion proteins were tested by LIPS on healthy controls, subjects with other kidney disease and subjects with MN. LIPS testing with both reporters detected robust PLA R autoantibody levels in a subset of patients with primary MN and demonstrated 100% sensitivity compared to ELISA and/or Western blotting. The PLA R-NanoLuc LIPS assay demonstrated 100% specificity matching the ELISA, but the specificity of the PLA R-Gluc LIPS assays was slightly lower (97%). Further analysis revealed that autoantibody levels determined by PLA R-NanoLuc LIPS correlated well with urinary protein excretion (R=0.79) and disease activity and was very sensitive for detecting clinical relapse. These results highlight the potential utility of the LIPS PLA R-NanoLuc assay for diagnosis and management of MN.
[Mh] Termos MeSH primário: Autoanticorpos/sangue
Glomerulonefrite Membranosa/diagnóstico
Ensaios de Triagem em Larga Escala/métodos
Imunoensaio/métodos
Imunoprecipitação/métodos
Receptores da Fosfolipase A2/imunologia
[Mh] Termos MeSH secundário: Animais
Biomarcadores/sangue
Células COS
Estudos de Casos e Controles
Cercopithecus aethiops
Ensaio de Imunoadsorção Enzimática
Genes Reporter
Glomerulonefrite Membranosa/sangue
Glomerulonefrite Membranosa/imunologia
Glomerulonefrite Membranosa/terapia
Seres Humanos
Luciferases/genética
Valor Preditivo dos Testes
Receptores da Fosfolipase A2/genética
Proteínas Recombinantes de Fusão/genética
Proteínas Recombinantes de Fusão/imunologia
Recidiva
Reprodutibilidade dos Testes
Fatores de Tempo
Transfecção
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Biomarkers); 0 (Receptors, Phospholipase A2); 0 (Recombinant Fusion Proteins); EC 1.13.12.- (Luciferases)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE


  9 / 284 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28065518
[Au] Autor:Cattran DC; Brenchley PE
[Ad] Endereço:Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada. Electronic address: daniel.cattran@uhn.ca.
[Ti] Título:Membranous nephropathy: integrating basic science into improved clinical management.
[So] Source:Kidney Int;91(3):566-574, 2017 Mar.
[Is] ISSN:1523-1755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Idiopathic membranous nephropathy (INM) remains a common cause of the nephrotic syndrome in adults. The autoimmune nature of IMN was clearly delineated in 2009 with the identification of the glomerular-deposited IgG to be a podocyte receptor, phospholipase A2 receptor (PLA2R) in 70% to 75% of cases. This anti-PLA2R autoantibody, predominantly the IgG4 subclass, has been quantitated in serum using an enzyme-linked immunosorbent assay and has been used to aid diagnosis and monitor response to immunosuppressive therapy. In 2014, a second autoantigen, thrombospondin type 1 domain-containing 7A (THSD7A), was identified. Immunostaining of biopsy specimens has further detected either PLA2R or THSD7A antigen in the deposited immune complexes in 5% to 10% of cases autoantibody seronegative at the time of biopsy. Therefore, the term IMN should now be superseded by the term primary or autoimmune MN (AMN) (anti-PLA2R or anti-THSD7A positive) classifying ∼80% to 90% of cases previously designated IMN. Cases of secondary MN associated with other diseases show much lower association with these autoantibodies, but their true incidence in secondary cases still needs to be defined. How knowledge of the autoimmune mechanism and the sequential measurement of these autoantibodies is likely to change the clinical management and trajectory of AMN by more precisely defining its diagnosis, prognosis, and treatment is discussed. Their application early in the disease course to new and old therapies will provide additional precision to AMN management. We also review innovative therapeutic approaches on the horizon that are expected to lead to our ultimate goal of improved patient care in A(I)MN.
[Mh] Termos MeSH primário: Autoanticorpos/sangue
Autoimunidade
Glomerulonefrite Membranosa/imunologia
Imunoglobulina G/sangue
Glomérulos Renais/imunologia
Síndrome Nefrótica/imunologia
Receptores da Fosfolipase A2/imunologia
Trombospondinas/imunologia
[Mh] Termos MeSH secundário: Animais
Autoimunidade/efeitos dos fármacos
Glomerulonefrite Membranosa/sangue
Glomerulonefrite Membranosa/diagnóstico
Glomerulonefrite Membranosa/tratamento farmacológico
Seres Humanos
Imunossupressores/uso terapêutico
Glomérulos Renais/efeitos dos fármacos
Glomérulos Renais/patologia
Síndrome Nefrótica/sangue
Síndrome Nefrótica/diagnóstico
Síndrome Nefrótica/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Immunoglobulin G); 0 (Immunosuppressive Agents); 0 (Receptors, Phospholipase A2); 0 (Thrombospondins); 0 (thrombospondin type I domain containing 7A protein, human)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170110
[St] Status:MEDLINE


  10 / 284 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28028136
[Au] Autor:Le WB; Shi JS; Zhang T; Liu L; Qin HZ; Liang S; Zhang YW; Zheng CX; Jiang S; Qin WS; Zhang HT; Liu ZH
[Ad] Endereço:National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China; and.
[Ti] Título:HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-Related Membranous Nephropathy.
[So] Source:J Am Soc Nephrol;28(5):1642-1650, 2017 May.
[Is] ISSN:1533-3450
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Idiopathic membranous nephropathy (MN) is associated with HLA; however, the HLA allele involved remains unknown. To identify the HLA risk alleles associated with phospholipase A2 receptor (PLA2R)-related MN in the Chinese population, we sequenced the entire MHC region in DNA samples from 99 patients with PLA2R-related MN, 50 patients with PLA2R-unrelated MN, and 100 healthy subjects. Two HLA risk alleles, HLA-DRB1*15:01 and HLA-DRB3*02:02, independently and strongly associated with an increased risk of PLA2R-related MN. After adjusting for HLA-DRB1*15:01 and HLA-DRB3*02:02, no other alleles showed significant association with PLA2R-related MN. A replication study in an independent cohort of 293 participants with PLA2R-related MN and 285 healthy controls validated these findings. In a joint analysis, a multivariate logistic regression model confirmed that HLA-DRB1*15:01 (odds ratio [OR], 24.9; 95% confidence interval [95% CI], 15.3 to 42.6; =2.3×10 ) and HLA-DRB3*02:02 (OR, 17.7; 95% CI, 11.0 to 30.3; =8.0×10 ) independently and strongly associated with PLA2R-related MN. As many as 98.7% of patients with PLA2R-related MN, compared with 43.9% of control subjects, carried at least one HLA risk allele. Subjects with either risk allele had higher odds of developing PLA2R-related MN than those without a risk allele (OR, 98.9; 95% CI, 44.4 to 281.7; =2.5×10 ). These HLA risk alleles also associated with the age at disease onset in patients with PLA2R-related MN. In conclusion, our findings provide clear evidence that the HLA-DRB1*15:01 and HLA-DRB3*02:02 alleles independently and strongly associate with PLA2R-related MN in the Chinese population.
[Mh] Termos MeSH primário: Glomerulonefrite Membranosa/genética
Cadeias HLA-DRB1/genética
Cadeias HLA-DRB3/genética
Receptores da Fosfolipase A2/fisiologia
[Mh] Termos MeSH secundário: Adulto
Alelos
Grupo com Ancestrais do Continente Asiático
Feminino
Glomerulonefrite Membranosa/imunologia
Cadeias HLA-DRB1/imunologia
Cadeias HLA-DRB3/imunologia
Seres Humanos
Masculino
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (HLA-DRB1 Chains); 0 (HLA-DRB3 Chains); 0 (Receptors, Phospholipase A2)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170531
[Lr] Data última revisão:
170531
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161229
[St] Status:MEDLINE
[do] DOI:10.1681/ASN.2016060644



página 1 de 29 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde